近日,the STEP 5 Study Group在Nature Medicine杂志上发表了一篇题为 Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial 的文章,他们所进行的这项为期2年的STEP 5研究旨在评估与安慰剂相比,将每周一次皮下注射司马鲁肽 2.4 mg作为行为干预的辅助手段对肥胖或至少有一种体...
which may have been related to the slower dosing titration. He also noted that patients in the study did not receive dietary counseling, unlike in the STEP-2 trial, where weight loss with semaglutide was greater than in this study.
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. PMID: 33667417 Semaglutide lowers body weight in rodents via distributed neural pathways. PMID: 32213703 Semaglutide (...
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. PMID: 33667417 Semaglutide lowers body weight in rodents via distributed neural pathways. PMID: 32213703 Semaglutide (...
与其他GLP-1R激动剂相比,司美格鲁肽在减肥减重方面也表现出色。一项名为“Semaglutide Treatment Effect in People with Obesity”(STEP)的研究证明,与安慰剂组相比,服用司美格鲁肽的肥胖者在治疗期间取得了更显著的体重减轻。这对于多数2型糖尿病患者来说,既是治疗结果的一部分,也提供了额外的健康益处。
诺和诺德(Novo Nordisk)近日在2021年美国内分泌学会(ENDO 2021)年会上公布了semaglutide(司美格鲁肽)2.4mg皮下注射制剂治疗肥胖症STEP 3a期临床试验项目的最新结果。来自STEP 4试验的数据显示,与安慰剂相比,每周一次皮下注射(SC)2.4mg剂量se...
在《新英格兰医学杂志》(NEJM)公布的 STEP 3a 期临床试验研究的结果,研究结果显示司美格鲁肽减肥效果突出,在非糖尿病的人群中进行的试验中,该项目涉及超过 4500 例无 2 型糖尿病的肥胖或超重成人患者,接受司美格鲁肽治疗的肥胖症患者在 68 周内平均体重减轻 17-18%,试验显示安全且耐受性良好[1]。 ✔ 心血...
including in the STEP 2 trial (participants with T2DM, semaglutide 2.4mg versus 1.0mg versus placebo, with TBWL at 68 weeks of 9.64%, 6.99% and 3.42%, respectively) and the STEP 3 trial (participants with obesity who all received intensive lifestyle intervention with semaglutide 2.4 mg weekly...
STEP 2 investigated the efficacy and safety of semaglutide 2.4 mg for weight management in adults with overweight/obesity and T2D. Methods: This randomized, double-blind, double-dummy, placebo-controlled, phase 3 trial was conducted at 149 sites across 12 countries (NCT03552757). Adults aged ≥...
Davies M, Færch L, Jeppesen OK, et al; STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):97...